AHA Journals, Author Interviews, Genetic Research, Heart Disease / 08.03.2021
Polygenic Risk Score Identifies Patients with Average LDL Who Could Benefit from Statins
MedicalResearch.com Interview with:
Giordano Bottà, PhD
CEO and Co-founder
Allelica
The Polygenic Risk Score Company
MedicalResearch.com: What is the background for this study?
Response: Previous research identified that polygenic risk score (PRS) has the highest predictive power compared to other risk factors and identifies individuals with the same risk of those with familial hypercholesterolemia, but are invisible to traditional risk assessment. We explored for the first time the interplay between the main causes of atherosclerosis, LDL cholesterol and PRS. We were interested in helping cardiologists understand why some individuals have bad arteries full of plaques while others don't in presence of the same LDL levels and no additional risk factors. Our findings explain why this is the case: LDL does not affect everyone the same. We believe that we are at the forefront of a change of paradigm in cardiovascular risk assessment: LDL levels cannot be accessed without considering the genetics of an individual.
(more…)